** Medical device maker Medtronic's MDT.N shares rise 1% to $90.86
** U.S. FDA has approves co's deep brain stimulation system $(DBS)$ for use in patients with Parkinson's disease
** DBS uses a surgically implanted device called neurostimulator to send electrical signals to specific parts of the brain that have been affected by the neurological disorder
** The system adjusts the therapy to each person's brain activity in real time
** The tech will be available to Parkinson's patients who have been previously implanted with a neurostimulator, as well as future DBS patients - co
** Patient programmings in the United States will begin at select healthcare systems over the coming weeks with availability nationwide in the coming months - MDT
** MDT rose 4.7% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。